poisar

Stocks · News reference

aTyr Pharma Announces Third Quarter 2026 Results and Corporate Update

Fiscal.ai

aTyr Pharma reported its third quarter 2026 financial results and announced that it has reached alignment with the FDA on a Phase 3 study protocol for efzofitimod.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncDelveinsight

    Systemic Sclerosis Market to Exhibit Growth at a 3% CAGR During the Forecast Period (2026–2036) as Emerging Therapies Expand Treatment Opportunities | DelveInsight

    The systemic sclerosis market is valued at USD 1.9 billion in 2025 and is projected to grow at a 3% CAGR through 2036. Growth is driven by increasing disease awareness, diagnostic advancements, and an expanding pipeline of emerging therapies including anifrolumab, belimumab, efzofitimod, and nemolizumab. The U.S. accounts for 55% of the market, with approximately 232K diagnosed cases across the 7MM in 2025.

  2. SEC EDGARSEC EDGAR

    8-K filing — aTYR PHARMA INC (ATYR)

    Filed: 2026-11-06 AccNo: 0001339970-26-000085 Size: 457 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits